Overview
A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac.
Indication
Indicated as a sympatholytic and mydriatic. Impotence has been successfully treated with yohimbine in male patients with vascular or diabetic origins and psychogenic origins.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2024/05/28 | Early Phase 1 | Recruiting | |||
2020/04/15 | Early Phase 1 | Withdrawn | Nathaniel M. Robbins | ||
2020/01/18 | Phase 2 | Not yet recruiting | |||
2019/11/29 | Phase 2 | Withdrawn | |||
2019/11/29 | Phase 2 | Withdrawn | |||
2018/09/13 | Phase 1 | Completed | |||
2017/05/16 | Phase 1 | Completed | |||
2016/11/15 | Early Phase 1 | Terminated | |||
2015/09/04 | Not Applicable | Completed | |||
2015/06/12 | Not Applicable | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
YOHIMBINE TAB 5.4MG | odan laboratories ltd | 01901885 | Tablet - Oral | 5.4 MG | 12/31/1991 |
YOHIMBINE HCL 5.4MG | odan laboratories ltd | 01954342 | Tablet - Oral | 5.4 MG | 9/9/1996 |
YOHIMBINE TAB 2MG | welcker-lyster ltd., division of technilab inc. | 00206202 | Tablet - Oral | 2 MG | 12/31/1951 |
YOHIMBINE TAB 6MG | rougier pharma division of ratiopharm inc | 00843512 | Tablet - Oral | 6 MG | 12/31/1990 |
YOHIMBINE HYDROCHLORIDE TAB 2MG | odan laboratories ltd | 00885533 | Tablet - Oral | 2 MG | 12/31/1992 |
YOHIMBINE-ODAN 6MG | odan laboratories ltd | 01985604 | Tablet - Oral | 6 MG | 12/31/1992 |
YOHIMBINE HYDROCHLORIDE TABLETS 5.4MG | tanta pharmaceuticals inc | 02049155 | Tablet - Oral | 5.4 MG | 12/31/1994 |
YOCON TABLET 5.4MG | palisades pharmaceuticals inc. | 00795283 | Tablet - Oral | 5.4 MG | 12/31/1988 |
YOHIMBINE HCL 2MG | odan laboratories ltd | 01954504 | Tablet - Oral | 2 MG | 12/31/1992 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.